All posts of Dr. Phil Kuruvilla

Post-ASH 2018: Primary Analysis of a Phase I/IIa, Multicentre, Dose-Escalation Study of MOR202 for R/R Multiple Myeloma

Oral presentation by Dr. Marc S. Raab Treatment for patients with relapsed/refractory (R/R) multiple myeloma (MM) is highly variable across Canada and depends on a variety of patient, disease-type, and funding factors. The present management paradigm is to generally treat these patients with a triplet, which could include an alkylating agent, an immunomodulatory drug (IMiD), […]

Post-ASH 2018: Use of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk MDS with Ring Sideroblasts Who Require RBC Transfusions

Oral presentation by Dr. Alan F. List The present treatment for patients with myelodysplastic syndromes (MDS) who require red blood cell (RBC) transfusions is extremely limited and includes clinical trials or best supportive care. Many agents have been studied over the past few years, but none have been shown to be of benefit. Patients with […]

The RELEVANCE Trial: Rituximab and Lenalidomide in Patients with Previously Untreated Follicular Lymphoma

Oral presentation by Dr. Frank Morschhauser Rituximab with chemotherapy has been the standard of care for patients with advanced stage, previously untreated follicular lymphoma (FL) for some time. The RELEVANCE trial compared chemotherapy with rituximab to a novel, non-chemotherapy approach of lenalidomide and rituximab in patients with previously untreated FL. At EHA 2018, data from the […]

A Final Analysis of Overall Survival from the CLL11 Study

Oral Presentation by Dr. Valentin Goede At EHA 2018, Dr. Goede presented the final survival analysis for one of our standard therapies for elderly, unfit patients with chronic lymphocytic leukemia (CLL). The phase III CLL11 study evaluated the efficacy and safety of obinutuzumab plus chlorambucil (G-Clb) and rituximab plus chlorambucil (R-Clb) versus chlorambucil alone (stage 1), […]